The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.a

Pneumonitis (interstitial lung disease/ILD)

Publications

Yu L, Guo QM, Liu L, Wang Y, Chen F, Zhang XT

Long-term survival with tocilizumab treatment for tislelizumab-related pneumonitis in a patient with non-small cell lung cancer: A case report.

Oncology letters 2026 Aug;32 — 2026 Aug — 344

Yu J, Liu X, Ma X, Liang L, Liu Y, Yin W, Li Q, Cao B, Liu W

Recurrent Checkpoint Inhibitor-Related Pneumonitis Refractory to Corticosteroid Treatment: A Case Report and Literature Review.

Clinical pharmacology : advances and applications 2025;17 — 2025 — 235-242

Daei Sorkhabi A, ZareDini M, Fazlollahi A, Sarkesh A, Naseri A, Mousavi SE, Nejadghaderi SA, Sullman MJM, Kolahi AA, Safiri S

The safety and efficacy of tislelizumab, alone or in combination with chemotherapy, for the treatment of non-small cell lung cancer: a systematic review of clinical trials.

BMC pulmonary medicine 2023 Dec 08;23;495 — 2023 Dec 08 — 495

Chen Z, He J

Infliximab in the treatment of tislelizumab-induced steroid-refractory immune checkpoint inhibitor-related pneumonia: case report and literature review.

Translational cancer research 2022 Sep;11;3309-3314 — 2022 Sep — 3309-3314

Cheng Y, Wang XM, Hu Q, Sun K, Zhao X, Zhang M, Wang G, Wang H, Xiong Y

Imaging Mass Cytometry Analysis of immune Checkpoint Inhibitor-Related Pneumonitis: A Case Report.

Frontiers in immunology 2022;13;899971 — 2022 — 899971

Deng C, Yang M, Jiang H, Wang R, Yang Z, Sun H, Cui H

Immune-Related Multiple-Organs Injuries Following ICI Treatment With Tislelizumab in an Advanced Non-Small Cell Lung Cancer Patient: A Case Report.

Frontiers in oncology 2021;11;664809 — 2021 — 664809

Song Y, Gao Q, Zhang H, Fan L, Zhou J, Zou D, Li W, Yang H, Liu T, Wang Q, Lv F, Guo H, Yang L, Elstrom R, Huang J, Novotny W, Wei V, Zhu J

Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study.

Leukemia 2020 Feb;34;533-542 — 2020 Feb — 533-542